The role of vitamin D in the brain and related neurological diseases

Abstract

Vitamin D is a steroid hormone that is produced photochemically in epidermis. It is known that vitamin D involved in the regulation of bone mineralization and calcium-phosphorus balance. However, in recent studies have suggested that vitamin D may have a significant impact in the development of the cell proliferation, differentiation, neurotransmission, neuroplasticity, neurotropic and neuroprotective effects in central nervous system (CNS). For the reason of the effects, it can be considered as a neurosteroid was reported. It was discussed that the level of vitamin D may be associated to neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS). The role of vitamin D and the mechanisms of these diseases will be discussed in the review. J Clin Exp Invest 2013; 4 (3): 411-415

Keywords

• Vitamin D, neurosteroid, brain, neurologic diseases

The role of vitamin D in the brain and related neurological diseases

Öz

D vitamini, epidermisde fotokimyasal olarak üretilen bir steroid hormondur. D vitaminin kemik mineralizasyonu ve kalsiyum-fosfor dengesinin düzenlenmesinde rolü olduğu bilinmektedir. Ancak son yapılan çalışmalarda, D vitamininin beyinde önemli etkilere sahip olabileceği ve santral sinir sisteminde (SSS) hücre proliferasyonunda, diferansiyasyonda, nörotransmisyonda, nöroplastisitede farklı değişken rollere sahip olduğu ve nörotrofik, nöroprotektif etki gösterdiği belirtilmiştir. Bu etkilerinden dolayı nörosteroid olarak kabul edilebileceği rapor edilmiştir. D vitamini seviyesinin nörodejeneratif hastalıklar olan Parkinson hastalığı, Alzheimer hastalığı, Multipl skleroz (MS), amiyotrofik lateral skleroz (ALS) ile ilişkili olabileceği tartışılmaktadır. Bu derlemede bu hastalıklarda D vitamininin oynadığı rol ve mekanizmaları tartışılacaktır

Anahtar Kelimeler

• D vitamini, nörosteroid, beyin, nörolojik hastalıklar

References

1. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:8-28.
2. Ohyama Y, Ozono K, Uchida M, et al. Identification of a vitamin D-responsive element in the 5-flanking region of the rat 25-hydroxyvi-tamin D3 24-hydroxylase gene. J Biol Chem 1994;269:10545–10550.
3. Hoenderop JG, Chon H, Gkika D, et al. Regulation of gene expression by dietary Ca2 in kidneys of 25-hy- droxyvitamin D3-1-hydroxylaseknockout mice. Kidney Int 2004;65:531–539
4. Ünal T, Çayır A, Kaya A, et al. Is low serum 25(OH) vi- tamin D a risk factor for childhood pneumonias? Dicle Med J 2012;3: 531-535
5. Eyles DW, Burne TH, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol 2012;34:47-64.
6. Harms LR, Burne TH, Eyles DW, et al. Vitamin D and the brain. Best Pract Res Clin Endocrinol Metab 2011;25:657-669.
7. Gumireddy K, Ikegaki N, Phillips PC, et al. Effect of 20-epi-1alpha,25-dihydroxyvitamin D3 on the prolifer- ation of human neuroblastoma: role of cell cycle regu- lators and the Myc-Id2 pathway. Biochem Pharmacol 2003;65:1943-1955.
8. Walbert T, Jirikowski GF, Prüfer K. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactiv- ity in the limbic system of the rat. Horm Metab Res 2001;33:525-531.

9. Lv Z, Tang B, Sun Q, et al. Association study between vitamin d receptor gene polymorphisms and patients with Parkinson disease in chinese han population. Int J Neurosci 2013;123:60-64.
10. Deluca GC, Kimball SM, Kolasinski J, et al. The Role of Vitamin D in Nervous System Health and Disease. Neuropathol Appl Neurobiol 2013 [Epub ahead of print]
11. Taniura H, Ito M, Sanada N, et al. Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J Neurosci Res 2006;83:1179-1189.
12. Veenstra TD, Prüfer K, Koenigsberger C, et al. 1,25-Di- hydroxyvitamin D3 receptors in the central nervous system of the rat embryo. Brain Res 1998;804:193- 205.
13. Sanchez B, Relova JL, Gallego R, et al. 1,25-Dihy- droxyvitamin D3 administration to 6-hydroxydopa- mine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hy- droxylase expression in substantia nigra and striatum. J Neurosci Res 2009;87:723-732.
14. Marini F, Bartoccini E, Cascianelli G, et al. Effect of 1alpha,25-dihydroxyvitamin D3 in embryonic hippo- campal cells. Hippocampus 2010;20:696-705.
15. Van Etten E, Decallonne B, Mathieu C. 1,25-dihy- droxycholecalciferol: endocrinology meets the im- mune system. Proc Nutr Soc 2002;61:375-380.
16. Atif F, Sayeed I, Ishrat T, et al. Progesterone with vi- tamin D affords better neuroprotection against excito- toxicity in cultured cortical neurons than progesterone alone. Mol Med 2009;15:328-336.
17. Ibi M, Sawada H, Nakanishi M, et al. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesence- phalic culture. Neuropharmacology 2001;40:761-771.
18. Wang T, Bengtsson G, Kärnefelt I, et al. Provitamins and vitamins D2 and D3 in Cladina spp. over a latitu- dinal gradient: possible correlation with UV levels. J Photochem Photobiol B 2001;62:118-122.
19. Evatt ML, Delong MR, Khazai N, et al. Prevalence of vitamin d insufficiency in patients with Parkin- son disease and Alzheimer disease. Arch Neurol 2008;65:1348-1352.
20. McGrath JJ, Burne TH, Féron F, et al. Developmental vitamin D deficiency and risk of schizophrenia: a 10- year update. Schizophr Bull 2010;36:1073-1078.
21. Newmark HL, Newmark J. Vitamin D and Parkinson’s disease--a hypothesis. Mov Disord 2007;22:461-468.
22. Wilkins CH, Sheline YI, Roe CM, et al. Vitamin D defi- ciency is associated with low mood and worse cogni- tive performance in older adults. Am J Geriatr Psy- chiatry 2006;14:1032-1040.
23. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of stria- tal fluorodopa F18 activity. Arch Neurol 2005;62:378- 382.
24. Furtada S, Payami H, Lockhart PJ, et al. Profile of families with parkinsonism-predominant spinocere- bellar ataxia type 2 (SCA2) Mov. Disord 2004;19:622- 629.
25. Kim JS, Kim YI, Song C, et al. Association of vitamin D receptor gene polymorphism and Parkinson’s disease in Koreans. J Korean Med Sci 2005;20:495-498.
26. Lv Z, Tang B, Sun Q, et al. Association study between vitamin d receptor gene polymorphisms and patients with Parkinson disease in chinese han population. Int J Neurosci 2013;123:60-64.
27. Kholodilov N, Yarygina O, Oo TF, et al. Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell line- derived neurotrophic factor in their targets. J Neurosci 2004;24:3136-3148.
28. Tekes K, Gyenge M, Folyovich A, et al. Influence of neonatal vitamin A or vitamin D treatment on the con- centration of biogenic amines and their metabolites in the adult rat brain. Horm Metab Res 2009;41:277-280.
29. Evatt ML, Delong MR, Khazai N, et al. Prevalence of vitamin d insufficiency in patients with Parkin- son disease and Alzheimer disease. Arch Neurol 2008;65:1348-1352.
30. Sato Y, Honda Y, Iwamoto J, et al. Abnormal bone and calcium metabolism in immobilized Parkinson’s disease patients. Mov Disord 2005;20:1598-1603.
31. Knekt P, Kilkkinen A, Rissanen H, et al. Serum vitamin D and the risk of Parkinson disease. MArch Neurol 2010;67:808-811.
32. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseas- es. Am J Clin Pathol 2008;129:526-529.
33. Perry TL, Yong VW. Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione me- tabolism in the substantia nigra of patients. Neurosci Lett 1986:30;67:269-274.
34. Garcion E, Sindji L, Leblondel G, et al. 1,25-dihy- droxyvitamin D3 regulates the synthesis of gamma- glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem 1999;73:859-866.
35. Bol Y, Smolders J, Duits A, et al. Fatigue and heat sensitivity in patients with multiple sclerosis. Acta Neurol Scand 2012;126:384-389.
36. Dörr J, Döring A, Paul F. Can we prevent or treat multiple sclerosis by individualized vitamin D supply? EPMA J 2013:29;4:4.
37. Minen MT, Karceski S. Multiple sclerosis and disease- modifying therapies. Neurology 2011;77:26-30.
38. Summerday NM, Brown SJ, Allington DR, et al. Vi- tamin D and multiple sclerosis: review of a possible association. J Pharm Pract 2012;25:75-84.
39. Hardy J, Selkoe DJ. The amyloid hypothesis of Al- zheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
40. Soni M, Kos K, Lang IA, et al. Vitamin D and cognitive function. Scand J Clin Lab Invest Suppl. 2012;243:79- 82.
41. Annweiler C, Llewellyn DJ, Beauchet O. Low Serum Vitamin D Concentrations in Alzheimer’s Disease: A Systematic Review and Meta-Analysis. J Alzheimers Dis 2013;33:659-674.
42. Qiao DL, Zhang SQ, Giunta B. Is vitamin D benefi- cial to Alzheimer disease? A surprising dilemma. CNS Neurosci Ther. 2012;18:601-603.
43. Annweiler C, Herrmann FR, Fantino B, et al. Effective- ness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn Behav Neurol 2012;25:121- 127.
44. Annweiler C, Allali G, Allain P, et al. Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol 2009;16:1083-1089.
45. Gianforcaro A, Solomon JA, Hamadeh MJ. Vitamin D(3) at 50x AI Attenuates the Decline in Paw Grip Endurance, but Not Disease Outcomes, in the G93A Mouse Model of ALS, and Is Toxic in Females. PLoS One 2013;8:302-343.
46. Karam C, Scelsa SN. Can vitamin D delay the pro- gression of ALS? Med Hypotheses 2011;76:643-645.
47. Devos D, Moreau C, Lassalle P, et al. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 2004;62:2127–2129.
48. Chabas JF, Alluin O, Rao G, et al. Vitamin D2 po- tentiates axon regeneration. J Neurotrauma 2008;25:1247–1256.